Discover
OncLive® On Air
OncLive® On Air
Author: OncLive® On Air
Subscribed: 128Played: 6,715Subscribe
Share
Description
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
946 Episodes
Reverse
Welcome to OncLive On Air®! I’m your host today, Chris Ryan.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today’s episode, we spoke with Paul K. Paik, MD, about long-term responses to tepotinib (Tepmetko) in patients with advanced non–small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. Dr Paik is clinical director of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, New York.In our exclusive interview, Dr Paik discussed a subset analysis of the phase 2 VISION trial (NCT02864992) presented at the 2026 ASCO Annual Meeting that profiled patients with long-term responses to tepotinib. Additionally, he explained where patients with MET exon 14 skipping alterations are missed in clinical practice and how he chooses among MET inhibitors and positions them relative to immunotherapy. Finally, Dr Paik shared his approach to managing peripheral edema and other adverse effects (AEs) of selective MET inhibitors.In VISION, 8.3% of patients (n = 313) with MET exon 14 skipping NSCLC achieved a duration of response to tepotinib longer than 36 months (range, 36.6-78.9) as of the May 20, 2024, data cutoff; their median duration of treatment was 50.7 months (range, 15.9-83.1). Dr Paik noted that these patients were largely similar to the overall population in their clinical characteristics and co-alterations; high-level MET amplification was found in 13.6% of patients with available sequencing data (n = 22). Of the 12 long-term responders who discontinued tepotinib, 5 did so because of AEs. Four patients who stopped early because of AEs prior to progression had responses that continued for up to 52 months without further anticancer therapy, which Dr Paik said points to biology worth studying to extend responses in other patients.In the overall VISION population after at least 3 years of follow-up, tepotinib generated an objective response rate of 51.8% (95% CI, 46.1%-57.4%) and a median overall survival of 19.7 months (95% CI, 16.2-22.3). Dr Paik favors first-line use, citing limited data on immunotherapy in this older population and retrospective data suggesting poor responses to immunotherapy despite frequently high PD-L1 expression. To manage edema, he described holding tepotinib, sometimes for weeks, before restarting, potentially at a reduced dose.That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.
In this episode of Oncology Unplugged, Chandler Park, MD, MSc, FACP, of Norton Cancer Institute in Louisville, Kentucky, spoke with Tejas Patil, MD, an assistant professor of medicine and vice head of Clinical Affairs in the Division of Medical Oncology at the University of Colorado School of Medicine and the clinical research director of thoracic oncology at the University of Colorado Cancer Center, about lung cancer advances presented at the 2026 ESMO Congress.The experts discussed small cell lung cancer (SCLC), highlighting the phase 3 DeLLphi-305 trial (NCT06211036) of maintenance tarlatamab-dlle (Imdelltra) plus durvalumab (Imfinzi) in extensive-stage disease. Dr Patil called it potentially the most important study of the meeting, noting an improved median overall survival with the combination than with durvalumab alone. He noted, however, that any-grade cytokine release syndrome occurred in almost half of patients, and he emphasized that standardized order sets, nursing education, and access to tocilizumab (Actemra) and corticosteroids are key to managing this toxicity. Dr Patil also discussed the phase 3 MAVERICK/SWOG S1827 trial, in which cognitive failure–free survival favored MRI surveillance over prophylactic cranial irradiation in extensive-stage SCLC.In EGFR-mutant non–small cell lung cancer, Dr Patil said nearly all patients should receive upfront treatment intensification, either with osimertinib (Tagrisso) plus chemotherapy per the phase 3 FLAURA2 trial (NCT04035486) or amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) per the phase 3 MARIPOSA trial (NCT04487080). Additionally, the experts noted that in the phase 3 SAFFRON trial (NCT05261399), osimertinib plus savolitinib yielded a longer median OS vs chemotherapy in patients with MET overexpression or amplification. Dr Patil also noted that divarasib (GDC-6036/RG6330) reduced the risk of progression or death vs sotorasib (Lumakras) or adagrasib (Krazati) in patients with KRAS G12C–mutant disease in the phase 3 Krascendo 1 trial (NCT06497556). He also cautioned against applying the FDA complete response letter for ivonescimab plus chemotherapy to the entire PD-1/VEGF class, noting that OS, a co-primary end point of the phase 3 HARMONi trial (NCT06396065), was not met in the cohort of patients with EGFR-mutant disease.
Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of localized prostate cancer diagnosis and management for 2026, reflecting the rapidly changing landscape of staging, systemic therapy, and perioperative treatment.The discussion began with disease presentation and risk assessment, noting that most cases are screen detected by elevated prostate-specific antigen levels and that prostate MRI is increasingly performed before biopsy. Drs Armstrong and Tawagi reviewed risk factors, such as older age, family history, Black African ancestry, and BRCA2 variants. They also explained the TNM staging system, Gleason grading, and National Comprehensive Cancer Network risk stratification. They emphasized that node-positive disease is stage IV in prostate cancer. They also highlighted the expanded role of prostate-specific membrane antigen PET imaging, particularly for high-risk and very high–risk disease, as well as the use of genomic classifiers.Regarding treatment, they described observation for patients with limited life expectancy, active surveillance, radiation, brachytherapy, and prostatectomy for low-risk disease, as well as radiation with 2 to 3 years of androgen deprivation therapy for high-risk disease. They noted that patients with very high–risk disease should also receive 2 years of abiraterone acetate (Zytiga) plus prednisone. They compared LHRH agonists, which require bicalutamide (Casodex) to prevent testosterone flare, with the antagonists degarelix (Firmagon) and relugolix (Orgovyx). Additionally, they reviewed androgen deprivation therapy (ADT)–associated toxicities and bone health management. Drs Armstrong and Tawagi also addressed biochemical recurrence and salvage radiation, and they concluded by highlighting recent data readouts.
In today's episode, we spoke with Zev A. Wainberg, MD, MSc, about subgroup data from the phase 3 RASolute 302 trial (NCT06625320) of daraxonrasib (Rasonque) in patients with previously treated metastatic pancreatic cancer, which were presented at the 2026 ESMO Congress. Dr Wainberg is a professor of medicine at the David Geffen School of Medicine at UCLA and co-director of the UCLA GI Oncology Program in Los Angeles, California.In our exclusive interview, Dr Wainberg discussed how daraxonrasib improved overall survival (OS) vs investigator’s choice of standard-of-care chemotherapy across RAS genotype subgroups, preselected chemotherapy regimens, and prior treatment settings. Additionally, Dr Wainberg shared practical advice for managing rash and stomatitis, including treatment holds and dose reductions. Finally, Dr Wainberg explained how RAS(ON) inhibition is moving into earlier lines of therapy and why he supports genomic testing at diagnosis.Dr Wainberg presented the analyses at the 2026 ESMO Congress on behalf of the RASolute 302 investigators. The trial randomly assigned 500 patients with metastatic pancreatic adenocarcinoma who had received 1 prior fluoropyrimidine- or gemcitabine-based regimen in the metastatic setting to daraxonrasib at 300 mg once daily (n = 248) or investigator’s choice of chemotherapy (n = 252). In the primary analysis, daraxonrasib generated a median OS of 13.2 months (95% CI, 10.0-not estimable) vs 6.7 months (95% CI, 5.8-8.0) with chemotherapy (HR, 0.40; 95% CI, 0.30-0.53; P = 4.6 × 10–11).Dr Wainberg first addressed the subgroup findings by RAS genotype. RAS G12D and G12V mutations predominated, accounting for 43.2% and 35.6% of the study population, respectively, and Dr Wainberg noted that nearly every genotype subgroup favored daraxonrasib for OS. The OS HRs were 0.49 (95% CI, 0.33-0.74) in the G12D subgroup (n = 95 vs 121), 0.32 (95% CI, 0.19-0.54) in the G12V subgroup (n = 102 vs 76), 0.61 (95% CI, 0.29-1.30) in the G12R subgroup (n = 30 vs 31), and 0.43 (95% CI, 0.09-1.98) in patients with no RAS mutation identified (n = 9 vs 7). Turning to sequencing, Dr Wainberg explained that neither the first-line regimen nor the chemotherapy selected for the control arm appeared to change the benefit of daraxonrasib. The OS HR was 0.45 (95% CI, 0.32-0.65) when gemcitabine plus nab-paclitaxel (Abraxane) was the preselected comparator (n = 140 vs 141), 0.46 (95% CI, 0.23-0.95) for pooled modified FOLFIRINOX or FOLFOX (n = 30 vs 30), and 0.32 (95% CI, 0.18-0.58) for nanoliposomal irinotecan (Onivyde) plus 5-fluorouracil and leucovorin (n = 78 vs 81).Looking ahead, Dr Wainberg noted that trials of RAS(ON) inhibition are already enrolling in the adjuvant and first-line settings, and that many KRAS inhibitors presented at the meeting are moving quickly to phase 3 studies.
In this episode of Oncology Unplugged, host Chandler Park, MD, MSc, FACP, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by John L. Marshall, MD, the chief of hematology and oncology, a professor of medicine and oncology, and the director of the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.Their discussion centered on the evolution of pancreatic adenocarcinoma management over the past several decades, culminating in the emergence of RAS-directed therapy. Drs Park and Marshall traced the treatment history from early regimens, such as fluorouracil/doxorubicin/mitomycin and single-agent fluorouracil, to the approval of gemcitabine based on clinical benefit, followed by years of gemcitabine-combination trials in which only capecitabine and nab-paclitaxel (Abraxane) produced positive results, and finally to FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin).Dr Marshall explained RAS biology, emphasizing that since most pancreatic cancers harbor RAS mutations, severing this pathway can produce meaningful clinical benefit with a single agent, unlike in colorectal cancer. The experts reviewed data from the phase 3 RASolute 302 trial (NCT06625320) of the pan-RAS inhibitor daraxonrasib (Rasonque) presented at the 2026 ASCO Annual Meeting, in which second-line therapy yielded a median overall survival improvement vs chemotherapy. Dr Marshall tempered enthusiasm for these efficacy data by noting that response rates remained below 50% and that rash, affecting approximately 80% of patients, requires proactive prophylaxis, close follow-up, and dermatology collaboration. He cautioned against offering the agent to patients with poor performance status and discussed dose-optimization strategies.Drs Park and Marshall also highlighted the importance of moving RAS inhibition into earlier lines of therapy, as only approximately 10% of patients are surgical candidates, as well as the need for comprehensive genomic testing, including germline BRCA1/2 testing to identify eligible candidates for treatment with olaparib (Lynparza). The conversation concluded with the potential role of artificial intelligence in predicting treatment benefit.








